Denali Therapeutics

DNLI · Nasdaq · United States

Share price · DNLI

$18.40-5.91 (-24.31%) 3M

close as of 2026-11-18 · 24h delayed · vol 2.4M (1.4x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when DNLI's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 4 Nov 2026+7.8%
  2. 14 Oct 2026-2.9%
  3. 14 Jul 2026-14.5%
  4. 15 Apr 2026+7.5%

    Nothing announced by DNLI that day or the session before.

  5. 26 Mar 2026-12.2%
  6. 22 Jan 2026+12.5%

    Nothing announced by DNLI that day or the session before.

  7. 6 Jan 2026+7.4%
  8. 10 Dec 2025-10.6%

Share of unusual movement by asset

For each asset, the share of DNLI's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Tividenofusp alfa (Avlayah)
events and moves
87%
BIIB122 / DNL151 (LRRK2 inhibitor)
events and moves
1shown from 8 days
DNL126
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—1%
Other company news (earnings, financing, releases naming no asset)—16%
Sessions with no dated event—76%

Assets

(4 total)
4Total Assets
1Approved
1Phase 3 / Filed
2Phase 1–2 / Early
4Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Approved
Iduronate-2-sulfatase (IDS)Protein / enzyme therapeutic
Mucopolysaccharidosis Type II
Phase 3
LRRK2Small molecule
Parkinson's Disease
Phase 1/2
SGSH replacement (TfR-mediated brain delivery)Protein / enzyme therapeutic
Mucopolysaccharidosis Type IIIA
Phase 1
MAPT mRNA (RNAi/ASO)RNA / oligonucleotide
Alzheimer's Disease

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
March 2027 (1)
BIIB122 / DNL151 (LRRK2 inhibitor)Phase 2Parkinson Disease
Est. primary completion 2027-03 · NCT06602193 · CT.gov ↗
What to watch
June 2027 (1)
Tividenofusp alfa · AvlayahPhase 2/3Mucopolysaccharidosis II
Est. primary completion 2027-06 · NCT06075537 · CT.gov ↗
What to watch
December 2027 (1)
Tividenofusp alfa · AvlayahPhase 2/3Mucopolysaccharidosis II
Est. primary completion 2027-12 · NCT05371613 · CT.gov ↗
What to watch
2031 (1)
February 2031 (1)
Tividenofusp alfa · AvlayahPhase 1/2Mucopolysaccharidosis II
Est. primary completion 2031-02 · NCT04251026 · CT.gov ↗
What to watch
2032 (1)
July 2032 (1)
DNL126Phase 1/2Mucopolysaccharidosis Type IIIA
Est. primary completion 2032-07 · NCT06181136 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(7)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

21 May 2026Topline resultBIIB122 (DNL151)Phase 2b LUMA (NCT05348785) did not meet its primary or secondary endpoints; development in idiopathic PD discontinued
Biogen and Denali Therapeutics · Source ↗
5 April 2026FDA action dateTividenofusp alfaFDA extends PDUFA date for tividenofusp alfa BLA to April 5, 2026
US, FDA · Source ↗
25 March 2026ApprovalTividenofusp alfaFDA grants accelerated approval of AVLAYAH for Hunter syndrome
US, FDA · Source ↗
24 March 2026ApprovalTividenofusp alfaFDA Boxed Warning on Avlayah (BLA761485)
US, FDA · FDA · Source ↗
7 July 2025Filing acceptedTividenofusp alfaFDA accepts BLA for tividenofusp alfa
US, FDA · Source ↗
7 July 2025Priority reviewTividenofusp alfaFDA grants Priority Review for tividenofusp alfa BLA
US, FDA · Source ↗
2 April 2025Filing submittedTividenofusp alfaRolling BLA submission initiated for tividenofusp alfa
US, FDA · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$18M$106M$106M+ $413M short-term inv.—-$117M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$3.6M$97M$205M+ $509M short-term inv.$128M-$97M operating cash flowreport ↗
2026-Q1—$104M$391M+ $600M short-term inv.$128M-$131M operating cash flowreport ↗
2025-Q3—$102M$94M+ $757M short-term inv.$127M-$107M operating cash flowreport ↗
2025-Q2—$103M$144M+ $758M short-term inv.$124M-$75M operating cash flowreport ↗
2025-Q1—$116M$60M+ $761M short-term inv.$133M-$131M operating cash flowreport ↗
2024-Q3$0$98M$92M+ $746M short-term inv.$107M-$59M operating cash flowreport ↗
2024-Q2$0$91M$76M+ $821M short-term inv.$99M-$91M operating cash flowreport ↗
2024-Q1$0$107M$62M+ $876M short-term inv.$102M-$114M operating cash flowreport ↗
2023-Q3$1.3M$90M$150M+ $961M short-term inv.$99M-$87M operating cash flowreport ↗
2023-Q2$294M$98M$134M+ $1.1B short-term inv.—-$113M operating cash flowreport ↗
2023-Q1$35M$129M$70M+ $1.2B short-term inv.$110M-$59M operating cash flowreport ↗
2022-Q3$0.2M$88M$120M+ $987M short-term inv.$103M-$57M operating cash flowreport ↗
2022-Q2$52M$93M$157M+ $914M short-term inv.$59M-$43M operating cash flowreport ↗
2022-Q1$42M$86M$106M+ $853M short-term inv.$65M-$72M operating cash flowreport ↗
2021-Q3$5.3M$72M$396M+ $645M short-term inv.$85M-$41M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0$419M$208M+ $663M short-term inv.$128M-$413M operating cash flowreport ↗

Denali reported revenue of $0M for 2025 (prior year $0M), R&D spend of $418.78M, up 5.6% YoY, and cash and equivalents of $208.43M, with total cash, cash equivalents and marketable securities of approximately $966.2M as of December 31, 2025. The company posted a full-year net loss of $512.54M, including a fourth-quarter net loss of $128.5M.

Denali established commercial launch readiness for tividenofusp alfa ahead of an April 5, 2026 PDUFA target action date for Hunter syndrome, and presented preliminary Phase 1/2 data for DNL126 supporting an accelerated approval path in Sanfilippo syndrome type A. Start-up activities are underway for DNL628 in Alzheimer’s disease and DNL952 in late-onset Pompe disease, with additional expected readouts including BIIB122 LUMA data in mid-2026 and eclitasertib Phase 2 results in the first half of 2026. Management expects to advance four to six additional programs into the clinic over the next three years, and the company completed a $275.0M synthetic royalty funding agreement with Royalty Pharma and a public offering totaling approximately $200.0M in net proceeds.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0$396M$177M+ $657M short-term inv.$106M-$348M operating cash flowreport ↗
2023-FY$331M$424M$129M+ $907M short-term inv.$36M-$358M operating cash flowreport ↗
2022-FY$105M$359M$220M+ $1.1B short-term inv.$82M-$245M operating cash flowreport ↗
2021-FY$49M$265M$295M+ $572M short-term inv.$73M-$211M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 7 sales ($1.3M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-17Schuth Alexander O. · COFO and SecretaryOption exercise16,566$9.60$159KForm 4
2026-11-17Schuth Alexander O. · COFO and SecretaryOption exercise (derivative)16,566——Form 4
2026-09-04Chin Peter Scott · Chief Medical OfficerOpen-market sale1,654$22.29$37KForm 4
2026-09-02Thornberry Nancy · directorOpen-market sale10,824$22.85$247KForm 4
2026-09-02Thornberry Nancy · directorOpen-market sale615$23.74$15KForm 4
2026-09-01Schuth Alexander O. · COFO and SecretaryOpen-market sale2,768$23.44$65KForm 4
2026-08-12Watts Ryan J. · director, President and CEOGift32,220——Form 4
2026-08-11Schuth Alexander O. · COFO and SecretaryOpen-market sale2,857$25.07$72KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 266 reporting institutions held 147.8M shares ($2.6B, 92.2% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.13,034,434$250.3M
2BAILLIE GIFFORD & CO12,066,479$231.7M
3Temasek Holdings (Private) Ltd7,012,974$134.6M
4STATE STREET CORP6,272,001$120.4M
5VANGUARD CAPITAL MANAGEMENT LLC6,147,957$118.0M
6VANGUARD PORTFOLIO MANAGEMENT LLC6,120,160$117.5M
7FMR LLC4,575,374$87.8M
8UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC4,432,314$85.1M
9GOLDMAN SACHS GROUP INC4,407,255$84.6M
10BAKER BROS. ADVISORS LP3,731,695$71.6M
11GEODE CAPITAL MANAGEMENT, LLC3,727,114$71.6M
12Holocene Advisors, LP3,195,429$61.4M
13DIMENSIONAL FUND ADVISORS LP2,692,175$51.7M
14UBS Group AG2,571,344$49.4M
15Pictet Asset Management Holding SA2,558,865$48.4M